Crawford Nomination Clears OIG Hurdle To Face Committee Vote, Plan B Hold
This article was originally published in The Tan Sheet
The conclusion of the HHS Inspector General's investigation into allegations against FDA Commissioner nominee Lester Crawford likely will bring the agency's delay of the Plan B emergency contraceptive switch application back into the foreground
You may also be interested in...
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner
Sens. Patty Murray (D-Wash.) and Hillary Clinton (D-N.Y.) followed through on their pledge to force a decision on the Plan B switch by placing a hold on Lester Crawford's nomination as FDA commissioner on June 15
Acting FDA Commissioner Lester Crawford's prospects for Senate confirmation appear to be in jeopardy after the Health Committee disclosed concerns about a conduct allegation lodged against the nominee